Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on ataluren pharmacokinetics in healthy Japanese adults
jRCT2071220020Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Primary pharmacokinetic endpoints. Started Jun 2022; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2071220020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220020.